In Vitro Toxicological Profile of Labetalol-Folic Acid/Folate Co-Administration in H9c2(2-1) and HepaRG Cells.
cytotoxicity
dietary supplements
folate
folic acid
labetalol
Journal
Medicina (Kaunas, Lithuania)
ISSN: 1648-9144
Titre abrégé: Medicina (Kaunas)
Pays: Switzerland
ID NLM: 9425208
Informations de publication
Date de publication:
10 Jun 2022
10 Jun 2022
Historique:
received:
06
05
2022
revised:
06
06
2022
accepted:
07
06
2022
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
28
6
2022
Statut:
epublish
Résumé
Background and Objectives: The consumption of dietary supplements has increased over the last decades among pregnant women, becoming an efficient resource of micronutrients able to satisfy their nutritional needs during pregnancy. Furthermore, gestational drug administration might be necessary to treat several pregnancy complications such as hypertension. Folic acid (FA) and folate (FT) supplementation is highly recommended by clinicians during pregnancy, especially for preventing neural tube birth defects, while labetalol (LB) is a β-blocker commonly administered as a safe option for the treatment of pregnancy-related hypertension. Currently, the possible toxicity resulting from the co-administration of FA/FT and LB has not been fully evaluated. In light of these considerations, the current study was aimed at investigating the possible in vitro cardio- and hepato-toxicity of LB-FA and LB-FT associations. Materials and Methods: Five different concentrations of LB, FA, FT, and their combination were used in myoblasts and hepatocytes in order to assess cell viability, cell morphology, and wound regeneration. Results: The results indicate no significant alterations in terms of cell viability and morphology in myoblasts (H9c2(2-1)) and hepatocytes (HepaRG) following a 72-h treatment, apart from a decrease in the percentage of viable H9c2(2-1) cells (~67%) treated with LB 150 nM−FT 50 nM. Additionally, LB (50 and 150 nM)−FA (0.2 nM) exerted an efficient wound regenerating potential in H9c2(2-1) myoblasts (wound healing rates were >80%, compared to the control at 66%), while LB-FT (at all tested concentrations) induced no significant impairment to their migration. Conclusions: Overall, our findings indicate that LB-FA and LB-FT combinations lack cytotoxicity in vitro. Moreover, beneficial effects were noticed on H9c2(2-1) cell viability and migration from LB-FA/FT administration, which should be further explored.
Identifiants
pubmed: 35744047
pii: medicina58060784
doi: 10.3390/medicina58060784
pmc: PMC9229417
pii:
doi:
Substances chimiques
Folic Acid
935E97BOY8
Labetalol
R5H8897N95
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
J Hypertens. 2014 May;32(5):1075-83; discussion 1083
pubmed: 24572430
Semin Perinatol. 2015 Nov;39(7):512-9
pubmed: 26452316
Xenobiotica. 2019 Dec;49(12):1504-1515
pubmed: 30865484
AJP Rep. 2020 Jul;10(3):e210-e212
pubmed: 33094006
Nutrients. 2020 Nov 24;12(12):
pubmed: 33255204
Sci Rep. 2015 Feb 17;5:8506
pubmed: 25687545
Sci Rep. 2019 Jul 11;9(1):10062
pubmed: 31296894
Hypertension. 2020 Jul;76(1):150-156
pubmed: 32389074
Medicina (Kaunas). 2022 Jan 22;58(2):
pubmed: 35208492
J Hum Nutr Diet. 2012 Apr;25(2):140-7
pubmed: 22126238
J Cell Mol Med. 2017 Dec;21(12):3277-3287
pubmed: 28608983
Am J Clin Nutr. 2010 Dec;92(6):1416-22
pubmed: 20844072
Drugs. 2014 Mar;74(3):283-96
pubmed: 24554373
Clin Nutr. 2022 Jan;41(1):246-254
pubmed: 34929527
Adv Chronic Kidney Dis. 2013 May;20(3):229-39
pubmed: 23928387
BMC Pregnancy Childbirth. 2021 May 8;21(1):364
pubmed: 33964896
J Inherit Metab Dis. 2011 Feb;34(1):101-9
pubmed: 20544289
Obstet Gynecol. 2020 Mar;135(3):623-633
pubmed: 32028492
Semin Perinatol. 2015 Nov;39(7):548-55
pubmed: 26344738
Xenobiotica. 2014 May;44(5):480-8
pubmed: 24494987
Turk J Med Sci. 2019 May 09;49(3):
pubmed: 31070342
Pharm Biol. 2017 Dec;55(1):1295-1303
pubmed: 28274156
Arch Gynecol Obstet. 2018 Oct;298(4):697-704
pubmed: 29978414
J Appl Toxicol. 2019 Jan;39(1):146-162
pubmed: 30182494
Cancers (Basel). 2021 Jul 21;13(15):
pubmed: 34359553
Saudi J Biol Sci. 2021 Jan;28(1):440-447
pubmed: 33424327
Cardiovasc Diagn Ther. 2019 Oct;9(Suppl 2):S424-S433
pubmed: 31737547
Rev Obstet Gynecol. 2011 Summer;4(2):52-9
pubmed: 22102928
Semin Perinatol. 2015 Nov;39(7):508-11
pubmed: 26358804
Nutrients. 2021 Sep 08;13(9):
pubmed: 34579011
Cardiol Clin. 2021 Feb;39(1):77-90
pubmed: 33222817
Cytotechnology. 2016 Dec;68(6):2407-2415
pubmed: 26946144
J Pharmacol Toxicol Methods. 2007 Nov-Dec;56(3):317-22
pubmed: 17662623
Ann N Y Acad Sci. 2018 Feb;1414(1):59-71
pubmed: 29155442
Front Cardiovasc Med. 2018 May 29;5:50
pubmed: 29896480
Stem Cell Res Ther. 2021 Mar 12;12(1):177
pubmed: 33712058
Int J Environ Res Public Health. 2022 Mar 29;19(7):
pubmed: 35409746
Molecules. 2021 Jun 18;26(12):
pubmed: 34207319
Expert Opin Drug Saf. 2015 Mar;14(3):453-61
pubmed: 25692529
Hormones (Athens). 2015 Apr-Jun;14(2):211-23
pubmed: 26158653